Literature DB >> 25520217

Natural Killer Cell Functional Activity After 4-1BB Costimulation.

Shadi sadat Navabi1, Mehrnoosh Doroudchi, Ahmad Hosseini Tashnizi, Mojtaba Habibagahi.   

Abstract

Reports show enhancement of CD8 T cells' activity through CD137 (4-1BB) signal; however, not all data proved similar effect in natural killer (NK) cells. Here, the impact of 4-1BB signal on NK cells' function was assessed during short term cultures. To that end, cytokine-activated NK cells were cocultured with adenovirally transduced MCF-7 stimulator cells expressing 4-1BB ligand. Cellular cytotoxicity, cytokine production, and expression of cytotoxicity related genes were assessed after overnight cultures. Sharp decrease of CD56+ and CD56bright NK cells was demonstrated. 4-1BB neither enhanced cellular degranulation nor improved IFN-γ production although it promoted granzyme B, perforin, and FasL gene expression. 4-1BB signal stimulated higher proportions of CD56bright population to degranulate and express CD107a; however, it could not recover killing activity against K562 targets. Our data could not show major promotion in activity of all NK subpopulations. Due to great heterogeneity of NK cells, more investigation is needed to draw a comprehensive conclusion.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25520217     DOI: 10.1007/s10753-014-0082-0

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  29 in total

1.  Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma.

Authors:  Beom K Choi; Young H Kim; Chang H Kim; Moon S Kim; Kwang H Kim; Ho S Oh; Myoung J Lee; Don K Lee; Dass S Vinay; Byoung S Kwon
Journal:  J Immunol       Date:  2010-07-07       Impact factor: 5.422

2.  4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells.

Authors:  Young-June Kim; Myung-Kwan Han; Hal E Broxmeyer
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

Review 3.  Real-time PCR for mRNA quantitation.

Authors:  Marisa L Wong; Juan F Medrano
Journal:  Biotechniques       Date:  2005-07       Impact factor: 1.993

Review 4.  Natural killer cell subsets in man and rodents.

Authors:  M Inngjerdingen; L Kveberg; C Naper; J T Vaage
Journal:  Tissue Antigens       Date:  2011-08

5.  Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Authors:  Duck Cho; David R Shook; Noriko Shimasaki; Yu-Hsiang Chang; Hiroyuki Fujisaki; Dario Campana
Journal:  Clin Cancer Res       Date:  2010-06-11       Impact factor: 12.531

6.  Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.

Authors:  Alexander C Dowell; Kimberley A Oldham; Rupesh I Bhatt; Steven P Lee; Peter F Searle
Journal:  Cancer Immunol Immunother       Date:  2011-10-22       Impact factor: 6.968

7.  Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.

Authors:  Hiroyuki Fujisaki; Harumi Kakuda; Noriko Shimasaki; Chihaya Imai; Jing Ma; Timothy Lockey; Paul Eldridge; Wing H Leung; Dario Campana
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

8.  Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody.

Authors:  Roch Houot; Holbrook Kohrt; Ron Levy
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

9.  CD56negCD16⁺ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection.

Authors:  Jeffrey M Milush; Sandra López-Vergès; Vanessa A York; Steven G Deeks; Jeffrey N Martin; Frederick M Hecht; Lewis L Lanier; Douglas F Nixon
Journal:  Retrovirology       Date:  2013-12-18       Impact factor: 4.602

10.  Role of inositol phospholipid signaling in natural killer cell biology.

Authors:  Matthew Gumbleton; William G Kerr
Journal:  Front Immunol       Date:  2013-03-06       Impact factor: 7.561

View more
  5 in total

1.  Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency.

Authors:  Mohammed F Alosaimi; Manfred Hoenig; Faris Jaber; Craig D Platt; Jennifer Jones; Jacqueline Wallace; Klaus-Michael Debatin; Ansgar Schulz; Eva Jacobsen; Peter Möller; Hanan E Shamseldin; Ferdous Abdulwahab; Niema Ibrahim; Hosam Alardati; Faisal Almuhizi; Ibraheem F Abosoudah; Talal A Basha; Janet Chou; Fowzan S Alkuraya; Raif S Geha
Journal:  J Allergy Clin Immunol       Date:  2019-03-11       Impact factor: 10.793

Review 2.  Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment.

Authors:  Olaf Oberschmidt; Stephan Kloess; Ulrike Koehl
Journal:  Front Immunol       Date:  2017-06-09       Impact factor: 7.561

3.  Current perspectives of SA-4-1BBL in immune modulation during cancer.

Authors:  Shu-Ni Zhou; Rui-Zhi Ran; Li-Li Tan; Hao Guo
Journal:  Exp Ther Med       Date:  2018-01-09       Impact factor: 2.447

4.  Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.

Authors:  Andrew S Flies; Nicholas B Blackburn; Alan Bruce Lyons; John D Hayball; Gregory M Woods
Journal:  Front Immunol       Date:  2017-05-03       Impact factor: 7.561

5.  Identification of CD137-Expressing B Cells in Multiple Sclerosis Which Secrete IL-6 Upon Engagement by CD137 Ligand.

Authors:  Hiu Yi Wong; Ankshita Prasad; Shu Uin Gan; John Jia En Chua; Herbert Schwarz
Journal:  Front Immunol       Date:  2020-11-06       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.